Diabetic Retinopathy: Pathogenesis, Clinical Features and the Role of Physical Activity in Prevention and Management
DOI:
https://doi.org/10.12775/QS.2026.50.67855Keywords
Diabetic retinopathy, Nonproliferative diabetic retinopathy, Proliferative diabetic retinopathy, Glycemic control, Physical activityAbstract
Background
Diabetic retinopathy (DR) is a vision-threatening microvascular complication of diabetes mellitus that affects the retina and is classified into non-proliferative (NDPR) and proliferative (PDR) forms with diabetic macular edema (DME) representing an additional sight-threatening manifestation.
Aim
This study provides a comprehensive overview of diabetic retinopathy, integrating current knowledge of its pathogenesis, risk factors, clinical features, diagnostic methods, treatment options and potential impact of physical activity on disease prevention and progression.
Material and methods
This study was conducted as a review of the selected literature on diabetic retinopathy available in the PubMed database. Keywords included “Diabetic retinopathy”, “Nonproliferative diabetic retinopathy”, “Proliferative diabetic retinopathy”, “Glycemic control”, “ Physical activity”.
Results
Diabetic retinopathy can remain asymptomatic for long periods, making regular eye examinations essential for its early detection. Strict control of blood glucose and blood pressure helps prevent the onset and slow the progression of diabetic retinopathy with inflammation playing a central role in its pathogenesis. In addition, physical activity is associated with a reduced risk of DR with a particularly strong protective effect against vision-threatening diabetic retinopathy (VTDR). Current treatments include intravitreal corticosteroids, anti-VEGF agents, vitrectomy and laser photocoagulation. Early diagnosis combined with optimized management can significantly reduce the risk of permanent visual loss.
Conclusion
Diabetic retinopathy is a primary contributor to vision loss in working-age adults in developed countries. Growing insights into its pathogenesis and the discovery of new therapeutic targets offer promising opportunities for improved treatment.
References
1. AlRubeaan, K., Abu ElAsrar, A. M., Youssef, A. M., et al. (2015). Diabetic retinopathy and its risk factors in a society with a type 2 diabetes epidemic: A Saudi National Diabetes Registry-based study. Acta Ophthalmologica, 93(2), e140-e147. doi:10.1111/aos.12532
2. Cole, J. B., & Florez, J. C. (2020). Genetics of diabetes mellitus and diabetes complications. Nature Reviews Nephrology, 16(7), 377-390. doi:10.1038/s41581-020-0278-5
3. Friedman, D. S., Ali, F., & Kourgialis, N. (2011). Diabetic retinopathy in the developing world: How to approach identifying and treating underserved populations. American Journal of Ophthalmology, 151(2), 192-194.e1. doi:10.1016/j.ajo.2010.10.014
4. Paul, S., Katare, R., D’Souza, S., et al. (2020). Molecular complexities underlying the vascular complications in diabetes mellitus. Journal of Diabetes and Its Complications, 34(10), 107613. doi:10.1016/j.jdiacomp.2020.107613
5. Stitt, A. W., Lois, N., Medina, R. J., Adamson, P., & Curtis, T. M. (2013). Advances in our understanding of diabetic retinopathy. Clinical Science (London, England: 1979), 125(1), 1-17. doi:10.1042/CS20120588
6. SimóServat, O., Hernández, C., & Simó, R. (2019). Diabetic retinopathy in the context of patients with diabetes. Ophthalmic Research, 62(4), 211-217. doi:10.1159/000499541
7. Amadio, M., Bucolo, C., Leggio, G. M., et al. (2010). The PKCbeta/HuR/VEGF pathway in diabetic retinopathy. Biochemical Pharmacology, 80(8), 1230-1237. doi:10.1016/j.bcp.2010.06.033
8. Frank, R. N. (2015). Diabetic retinopathy and systemic factors. Middle East African Journal of Ophthalmology, 22(2), 151-156. doi:10.4103/09749233.154388
9. Hendrick, A. M., Gibson, M. V., & Kulshreshtha, A. (2015). Diabetic retinopathy. Primary Care, 42(3), 451-464. doi:10.1016/j.pop.2015.05.005
10. Kollias AN, Ulbig MW. Diabetic retinopathy: Early diagnosis and effective treatment. Dtsch Arztebl Int. 2010;107(5):75-83. doi: 10.3238/arztebl.2010.0075.
11. Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig. 2021;12(8):1322-1325. doi: 10.1111/jdi.13480.
12. Chaudhary, S., Zaveri, J., & Becker, N. (2021). Proliferative diabetic retinopathy (PDR). Disease-A-Month, 67(5), 101140. doi:10.1016/j.disamonth.2021.101140
13. Simó, R. (2013). New insights in the pathogenesis and treatment of diabetic retinopathy. Current Medicinal Chemistry, 20(26), 3187-3188. doi:10.2174/0929867311320260001
14. Klein, R., & Klein, B. E. (2010). Are individuals with diabetes seeing better?: A long-term epidemiological perspective. Diabetes, 59(8), 1853-1860. doi:10.2337/db091904
15. Grauslund, J. (2022). Diabetic retinopathy screening in the emerging era of artificial intelligence. Diabetologia, 65(9), 1415-1423. doi:10.1007/s00125-022-05727-0
16. Lanzetta, P., Sarao, V., Scanlon, P. H., et al. (2020). Fundamental principles of an effective diabetic retinopathy screening program. Acta Diabetologica, 57(7), 785-798. doi:10.1007/s00592020-01506-8
17. Scanlon, P. H. (2019). Update on screening for sight-threatening diabetic retinopathy. Ophthalmic Research, 62(4), 218-224. doi:10.1159/000499539
18. Salz, D. A., & Witkin, A. J. (2015). Imaging in diabetic retinopathy. Middle East African Journal of Ophthalmology, 22(2), 145-150. doi:10.4103/0974-9233.151887
19. Antonetti, D. A., Klein, R., & Gardner, T. W. (2012). Diabetic retinopathy. The New England Journal of Medicine, 366(13), 1227-1239. doi:10.1056/NEJMra1005073
20. Tran, K., & PakzadVaezi, K. (2018). Multimodal imaging of diabetic retinopathy. Current Opinion in Ophthalmology, 29(6), 566-575. doi:10.1097/ICU.0000000000000524
21. Ren, C., Liu, W., Li, J., et al. (2019). Physical activity and risk of diabetic retinopathy: A systematic review and meta-analysis. Acta Diabetologica, 56(8), 823-837. doi:10.1007/s00592-019-01319-4
22. Simó, R., Hernández, C., & European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) (2014). Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends in Endocrinology and Metabolism, 25(1), 23-33. doi:10.1016/j.tem.2013.09.005
23. Chou, Y., Ma, J., Su, X., et al. (2020). Emerging insights into the relationship between hyperlipidemia and the risk of diabetic retinopathy. Lipids in Health and Disease, 19(1), 241. doi:10.1186/s12944-020-01415-3
24. Jenkins, A. J., Joglekar, M. V., Hardikar, A. A., et al. (2015). Biomarkers in diabetic retinopathy. The Review of Diabetic Studies, 12(1-2), 159-195. doi:10.1900/RDS.2015.12.159
25. AlShabrawey, M., Zhang, W., & McDonald, D. (2015). Diabetic retinopathy: Mechanism, diagnosis, prevention, and treatment. BioMed Research International, 2015, 854593. doi:10.1155/2015/854593
26. Yun, S. H., & Adelman, R. A. (2015). Recent developments in laser treatment of diabetic retinopathy. Middle East African Journal of Ophthalmology, 22(2), 157-163. doi:10.4103/0974-9233.150633
27. Selvaraj, K., Gowthamarajan, K., Karri, V. V. S. R., et al. (2017). Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy. Journal of Drug Targeting, 25(5), 386-405. doi:10.1080/1061186X.2017.1280809
28. Rodríguez, M. L., Pérez, S., MenaMollá, S., et al. (2019). Oxidative stress and microvascular alterations in diabetic retinopathy: Future therapies. Oxidative Medicine and Cellular Longevity, 2019, 4940825. doi:10.1155/2019/4940825
29. Kern, T. S., Antonetti, D. A., & Smith, L. E. H. (2019). Pathophysiology of diabetic retinopathy: Contribution and limitations of laboratory research. Ophthalmic Research, 62(4), 196-202. doi:10.1159/000500026
30. Kempen, J. H., O’Colmain, B. J., Leske, M. C., et al. (2004). The prevalence of diabetic retinopathy among adults in the United States. Archives of Ophthalmology, 122(4), 552-563. doi:10.1001/archopht.122.4.552
31. Simó, R. (2013). New insights in the pathogenesis and treatment of diabetic retinopathy. Current Medicinal Chemistry, 20(26), 3187-3188. doi:10.2174/0929867311320260001
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Wiktoria Marzec, Wiktoria Boral, Marek Dróżdż, Jan Puliński, Julia Linke, Michał Napierała, Szymon Stupnicki, Agnieszka Bajkacz, Bartosz Olkowski, Alicja Maczkowska

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 10
Number of citations: 0